DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients
Extranodal natural killer/T‐cell lymphoma, nasal type (ENKL) is a rare peripheral T‐cell lymphoma that predominantly occurs in Asian and South American populations. The treatment of ENKL has been a challenge for a long time. This study was conducted to compare the clinical efficacy and safety of cis...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.12893 |
| _version_ | 1818417277136011264 |
|---|---|
| author | Xin Wang Junxia Hu Meng Dong Mengjie Ding Linan Zhu Jingjing Wu Zhenchang Sun Xin Li Lei Zhang Ling Li Xinhua Wang Xiaorui Fu Guannan Wang Qingjiang Chen Mingzhi Zhang Xudong Zhang |
| author_facet | Xin Wang Junxia Hu Meng Dong Mengjie Ding Linan Zhu Jingjing Wu Zhenchang Sun Xin Li Lei Zhang Ling Li Xinhua Wang Xiaorui Fu Guannan Wang Qingjiang Chen Mingzhi Zhang Xudong Zhang |
| author_sort | Xin Wang |
| collection | DOAJ |
| description | Extranodal natural killer/T‐cell lymphoma, nasal type (ENKL) is a rare peripheral T‐cell lymphoma that predominantly occurs in Asian and South American populations. The treatment of ENKL has been a challenge for a long time. This study was conducted to compare the clinical efficacy and safety of cisplatin, dexamethasone, gemcitabine, and pegaspargase (DDGP) and methotrexate, dexamethasone, ifosfamide, L‐asparaginase, and etoposide (SMILE) regimens for relapsed/refractory ENKL and explore the prognostic factors. From October 2014 to July 2019, 54 patients with relapsed/refractory ENKL who received DDGP or SMILE chemotherapy were retrospectively assessed in this study. Thirty‐one patients received DDGP chemotherapy and 23 patients received SMILE chemotherapy. A higher complete response rate was observed in patients treated with DDGP regimen (61.3% vs. 30.4%, P = 0.025). The DDGP group (95% confidence interval (CI) of 5‐year progression‐free survival (PFS): 24.6–66.2%; 95% CI of 5‐year overall survival (OS): 8.5–91.7%) was also significantly associated with longer 5‐year PFS and 5‐year OS (P = 0.008 for 5‐year PFS, P = 0.023 for 5‐year OS). More serious leucopenia (P = 0.021), neutropenia (P = 0.041), and allergy (P = 0.040) were observed in the SMILE group. Post‐treatment Epstein–Barr virus (EBV)‐DNA status (P = 0.001 for PFS, P = 0.018 for OS) was identified as a significant prognostic factor for PFS and OS in multivariate analysis. The present research suggested that compared with SMILE chemotherapy, DDGP chemotherapy can significantly improve the response and survival of relapsed/refractory ENKL with better tolerance. Post‐treatment EBV‐DNA status was identified as a significant prognostic factor for PFS and OS in relapsed/refractory ENKL. |
| first_indexed | 2024-12-14T12:04:13Z |
| format | Article |
| id | doaj.art-4a34495626294e5a8aaa0e2f484eb6bd |
| institution | Directory Open Access Journal |
| issn | 1752-8054 1752-8062 |
| language | English |
| last_indexed | 2024-12-14T12:04:13Z |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj.art-4a34495626294e5a8aaa0e2f484eb6bd2022-12-21T23:01:55ZengWileyClinical and Translational Science1752-80541752-80622021-01-0114140541110.1111/cts.12893DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 PatientsXin Wang0Junxia Hu1Meng Dong2Mengjie Ding3Linan Zhu4Jingjing Wu5Zhenchang Sun6Xin Li7Lei Zhang8Ling Li9Xinhua Wang10Xiaorui Fu11Guannan Wang12Qingjiang Chen13Mingzhi Zhang14Xudong Zhang15Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Pathology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaExtranodal natural killer/T‐cell lymphoma, nasal type (ENKL) is a rare peripheral T‐cell lymphoma that predominantly occurs in Asian and South American populations. The treatment of ENKL has been a challenge for a long time. This study was conducted to compare the clinical efficacy and safety of cisplatin, dexamethasone, gemcitabine, and pegaspargase (DDGP) and methotrexate, dexamethasone, ifosfamide, L‐asparaginase, and etoposide (SMILE) regimens for relapsed/refractory ENKL and explore the prognostic factors. From October 2014 to July 2019, 54 patients with relapsed/refractory ENKL who received DDGP or SMILE chemotherapy were retrospectively assessed in this study. Thirty‐one patients received DDGP chemotherapy and 23 patients received SMILE chemotherapy. A higher complete response rate was observed in patients treated with DDGP regimen (61.3% vs. 30.4%, P = 0.025). The DDGP group (95% confidence interval (CI) of 5‐year progression‐free survival (PFS): 24.6–66.2%; 95% CI of 5‐year overall survival (OS): 8.5–91.7%) was also significantly associated with longer 5‐year PFS and 5‐year OS (P = 0.008 for 5‐year PFS, P = 0.023 for 5‐year OS). More serious leucopenia (P = 0.021), neutropenia (P = 0.041), and allergy (P = 0.040) were observed in the SMILE group. Post‐treatment Epstein–Barr virus (EBV)‐DNA status (P = 0.001 for PFS, P = 0.018 for OS) was identified as a significant prognostic factor for PFS and OS in multivariate analysis. The present research suggested that compared with SMILE chemotherapy, DDGP chemotherapy can significantly improve the response and survival of relapsed/refractory ENKL with better tolerance. Post‐treatment EBV‐DNA status was identified as a significant prognostic factor for PFS and OS in relapsed/refractory ENKL.https://doi.org/10.1111/cts.12893 |
| spellingShingle | Xin Wang Junxia Hu Meng Dong Mengjie Ding Linan Zhu Jingjing Wu Zhenchang Sun Xin Li Lei Zhang Ling Li Xinhua Wang Xiaorui Fu Guannan Wang Qingjiang Chen Mingzhi Zhang Xudong Zhang DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients Clinical and Translational Science |
| title | DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients |
| title_full | DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients |
| title_fullStr | DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients |
| title_full_unstemmed | DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients |
| title_short | DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients |
| title_sort | ddgp vs smile in relapsed refractory extranodal natural killer t cell lymphoma nasal type a retrospective study of 54 patients |
| url | https://doi.org/10.1111/cts.12893 |
| work_keys_str_mv | AT xinwang ddgpvssmileinrelapsedrefractoryextranodalnaturalkillertcelllymphomanasaltypearetrospectivestudyof54patients AT junxiahu ddgpvssmileinrelapsedrefractoryextranodalnaturalkillertcelllymphomanasaltypearetrospectivestudyof54patients AT mengdong ddgpvssmileinrelapsedrefractoryextranodalnaturalkillertcelllymphomanasaltypearetrospectivestudyof54patients AT mengjieding ddgpvssmileinrelapsedrefractoryextranodalnaturalkillertcelllymphomanasaltypearetrospectivestudyof54patients AT linanzhu ddgpvssmileinrelapsedrefractoryextranodalnaturalkillertcelllymphomanasaltypearetrospectivestudyof54patients AT jingjingwu ddgpvssmileinrelapsedrefractoryextranodalnaturalkillertcelllymphomanasaltypearetrospectivestudyof54patients AT zhenchangsun ddgpvssmileinrelapsedrefractoryextranodalnaturalkillertcelllymphomanasaltypearetrospectivestudyof54patients AT xinli ddgpvssmileinrelapsedrefractoryextranodalnaturalkillertcelllymphomanasaltypearetrospectivestudyof54patients AT leizhang ddgpvssmileinrelapsedrefractoryextranodalnaturalkillertcelllymphomanasaltypearetrospectivestudyof54patients AT lingli ddgpvssmileinrelapsedrefractoryextranodalnaturalkillertcelllymphomanasaltypearetrospectivestudyof54patients AT xinhuawang ddgpvssmileinrelapsedrefractoryextranodalnaturalkillertcelllymphomanasaltypearetrospectivestudyof54patients AT xiaoruifu ddgpvssmileinrelapsedrefractoryextranodalnaturalkillertcelllymphomanasaltypearetrospectivestudyof54patients AT guannanwang ddgpvssmileinrelapsedrefractoryextranodalnaturalkillertcelllymphomanasaltypearetrospectivestudyof54patients AT qingjiangchen ddgpvssmileinrelapsedrefractoryextranodalnaturalkillertcelllymphomanasaltypearetrospectivestudyof54patients AT mingzhizhang ddgpvssmileinrelapsedrefractoryextranodalnaturalkillertcelllymphomanasaltypearetrospectivestudyof54patients AT xudongzhang ddgpvssmileinrelapsedrefractoryextranodalnaturalkillertcelllymphomanasaltypearetrospectivestudyof54patients |